XNYS
CLB
Market cap506mUSD
Jul 09, Last price
10.99USD
1D
-1.43%
1Q
-33.43%
Jan 2017
-90.84%
Name
Core Laboratories N.V.
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector, delivering specialized services and products for characterizing subterranean reservoirs and optimizing hydrocarbon extraction. The company's operations are distinctly segmented into Reservoir Description and Production Enhancement. The Reservoir Description division meticulously analyzes petroleum reservoir rock, fluid, and gas samples. This detailed scientific examination aims to boost the yield and enhance the recovery of oil and gas from clients' reservoirs. Offerings in this segment encompass comprehensive laboratory analysis and on-site field evaluations to determine the properties of crude oil and refined products, alongside performing proprietary and collaborative industry research studies. Conversely, the Production Enhancement segment furnishes an array of services and products vital for well completions, perforations, stimulation processes, and general production activities. This includes providing integrated diagnostic tools designed to assess the efficacy of well completions and to devise strategies for more effective enhanced oil recovery initiatives. Core Laboratories markets and sells its solutions through diverse channels, including direct sales representatives, educational seminars, industry trade exhibitions, print advertising, and a network of distributors. Established in 1936, the company boasts a significant international presence, conducting operations in approximately 50 countries, with its corporate headquarters situated in Amstelveen, the Netherlands.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||